sFlt-1/PlGF Ratio Is Not a Good Predictor of Severe COVID-19 nor of Adverse Outcome in Pregnant Women with SARS-CoV-2 Infection—A Case-Control Study

Malicka, Ewa; Szymusik, Iwona; Rebizant, Beata; Dąbrowski, Filip; Brawura-Biskupski-Samaha, Robert; Kosińska-Kaczyńska, Katarzyna

doi:10.3390/ijerph192215054

Cited by 3 publications

(1 citation statement)

References 23 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another Polish retrospective study conducted by Malicka et al, COVID-19 was associated with higher sFlt-1/PlGF ratio. Authors compared group of 138 SARS-COV 2 positive pregnant and 140 negative controls, and observed significant differences in sFlt-1/PlGF ratio between SARS-CoV-2-positive 24 (3,7–51,5) and negative women 11,2 (2,1–23,4) p-value < 0,01 [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

Pluta,

Januszewski,

Ziuzia-Januszewska

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

The association between SARS-CoV-2 infection in pregnancy and preeclampsia is widely debated in numerous studies. The aim of our study was to investigate whether an increased sFlt-1/PlGF ratio is a good marker of preeclampsia in pregnant patients with COVID-19 infection. This single centre prospective study was conducted in the Department of Obstetrics and Gynaecology, at the Central Clinical Hospital of the Ministry of the Interior and Administration in Warsaw. The study group consisted of 68 COVID-19 pregnant patients and 57 SARS-CoV-2 negative pregnant controls. Serum sFlt-1/PlGF ratio was assessed. The two groups did not differ in terms of the frequency of IVF, nulliparity, history of hypertension, pre-gestational diabetes and chronic kidney disease. The primary outcome was the diagnosis of preeclampsia. Preeclampsia was diagnosed in 10 patients in both groups. The sFlt-1/PlGF ratio higher than 38, considered highly suggestive of developing preeclampsia, was found in 20 patients in the COVID-19 group and 15 patients in the control group. The odds of developing preeclampsia in patients with sFlt-1/PlGF ratio > 38 was approximately 4-fold higher in COVID-19 group and 11-fold higher in controls. Sflt-1/PlGF ratio does not differ significantly between the SARS-CoV-2-positive and SARS-COV-2-negative pregnant patients. The sFlt-1/PlGF ratio > 38 is associated with higher odds of the diagnosis of preeclampsia in both of these groups, and therefore may serve as its marker regardless of COVID-19 infection status.

show abstract

Section: Discussionmentioning

confidence: 99%

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

Pluta,

Januszewski,

Ziuzia-Januszewska

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

show abstract

SARS-CoV-2 seroprevalence and preeclampsia markers in Mozambican pregnant women with perinatal loss

Chileshe,

Nhampossa,

Carrilho

et al. 2024

BMC Pregnancy Childbirth

View full text Add to dashboard Cite

The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19

Kosińska-Kaczyńska

Malicka

Szymusik

et al. 2023

JCM

View full text Add to dashboard Cite

COVID-19 in pregnant women increases the risk of adverse pregnancy outcomes, including preeclampsia. This meta-analysis aimed to examine the effect of SARS-CoV-2 infection on sFlt-1/PIGF ratio during pregnancy. The study was designed as a systematic review and meta-analysis. PubMed, Web of Science, Embase and Cochrane Library were searched for relevant studies reporting the sFlt-1/PlGF ratio in pregnant women with COVID-19. Results were compared using meta-analysis by the Mantel–Haenszel method. A total of 7 studies were included in the analysis. sFlt-1/PlGF ratios between COVID-19 positive vs. negative women were 45.8 ± 50.3 vs. 37.4 ± 22.5, respectively (SMD = 1.76; 95% CI: 0.43 to 3.09; p = 0.01). sFlt-1/PlGF ratios between asymptomatic vs. symptomatic patients were 49.3 ± 35.7 vs. 37.1 ± 25.6 (SMD = 0.30; 95% CI: −0.35 to 0.95; p = 0.36). sFlt-1/PlGF ratio in non-severe group was 30.7 ± 56.5, compared to 64.7 ± 53.5 for severe patients (SMD = −1.88; 95% CI: −3.77 to 0.01; p = 0.05). sFlt-1/PlGF ratios in COVID-19 patients, with and without hypertensive disease of pregnancy, were 187.0 ± 121.8 vs. 21.6 ± 8.6, respectively (SMD = 2.46; 95% CI: 0.99 to 3.93; p = 0.001). Conclusions: Patients with COVID-19, as compared to patients without COVID-19, were characterized by higher sFlt-1/PlGF ratio. Moreover, severe COVID-19 and SARS-CoV-2 infection in hypertensive pregnant women was related to significantly higher sFlt-1/PlGF ratio.

show abstract

sFlt-1/PlGF Ratio Is Not a Good Predictor of Severe COVID-19 nor of Adverse Outcome in Pregnant Women with SARS-CoV-2 Infection—A Case-Control Study

Cited by 3 publications

References 23 publications

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

sFlT-1/PlGF ratio as a predictor of preeclampsia in COVID-19 pregnant patients

SARS-CoV-2 seroprevalence and preeclampsia markers in Mozambican pregnant women with perinatal loss

The sFlt-1/PlGF Ratio in Pregnant Patients Affected by COVID-19

Contact Info

Product

Resources

About